Chinese herbal formula Qilong-Lishui granule improves puromycin aminonucleoside-induced renal injury through regulation of bone morphogenetic proteins

Nephrology

Volumn 12, Issue 5, 2007, Pages 466-473

  Li, Ping ^a   Yan, Jing ^a   Sun, Yu ^b   Burczynski, Frank J ^b   Gong, Yuewen ^b  

^a CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Bone morphogenetic protein receptor; Chinese herbal formula; Nephrotic syndrome; Puromycin aminonucleoside; Transforming growth factor beta1

Indexed keywords

BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; CHINESE DRUG; FOSINOPRIL; PUROMYCIN AMINONUCLEOSIDE; QILONG LISHUI GRANULE; SMAD1 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG MECHANISM; DRUG MEGADOSE; ELECTRON MICROSCOPE; GENE EXPRESSION; HISTOPATHOLOGY; JUGULAR VEIN; KIDNEY INJURY; LOW DRUG DOSE; MALE; NEPHROTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL;

ANIMALS; BLOOD PROTEINS; BLOOD UREA NITROGEN; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; BONE MORPHOGENETIC PROTEINS; CHOLESTEROL; CREATININE; DRUGS, CHINESE HERBAL; FOSINOPRIL; KIDNEY; MICROSCOPY, ELECTRON; NEPHROTIC SYNDROME; PROTEINURIA; PUROMYCIN AMINONUCLEOSIDE; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SMAD1 PROTEIN; TRIGLYCERIDES;

EID: 34548394511     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2007.00828.x     Document Type: Article

References (43)

1. Orth SR, Ritz E. The nephrotic syndrome. N. Engl. J. Med. 1998 338 : 1202 11.
2. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N. Engl. J. Med. 1998 339 : 1448 56.
3. Olson JL, Rennke HG, Venkatachalam MA. Alterations in the charge and size selectivity barrier of the glomerular filter in aminonucleoside nephrosis in rats. Lab. Invest. 1981 44 : 271 9.
4. Bohrer MP, Baylis C, Robertson CR, Brenner BM, Troy JL, Willis WT. Mechanisms of the puromycin-induced defects in the transglomerular passage of water and macromolecules. J. Clin. Invest. 1977 60 : 152 61.
5. Whiteside C, Prutis K, Cameron R, Thompson J. Glomerular epithelial detachment, not reduced charge density, correlates with proteinuria in adriamycin and puromycin nephrosis. Lab. Invest. 1989 61 : 650 60.
6. Nakamura T, Ebihara I, Shirato I, Tomino Y, Koide H. Modulation of basement membrane component gene expression in glomeruli of aminonucleoside nephrosis. Lab. Invest. 1991 64 : 640 47.
7. Diamond JR, Karnovsky MJ. Focal and segmental glomerulosclerosis following a single intravenous dose of puromycin aminonucleoside. Am. J. Pathol. 1986 122 : 481 7.
8. Zeisberg M, Hanai J, Sugimoto H et al. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat. Med. 2003 9 : 964 8.
9. Wahab NA, Mason RM. A critical look at growth factors and epithelial-to-mesenchymal transition in the adult kidney.Interrelationships between growth factors that regulate EMT in the adult kidney. Nephron Exp. Nephrol. 2006 104 : e129 34.
10. Yanagita M. Modulator of bone morphogenetic protein activity in the progression of kidney diseases. Kidney Int. 2006 70 : 989 93.
11. Villa E, Rabano A, Ruilope LM, Garcia-Robles R. Effects of cicaprost and fosinopril on the progression of rat diabetic nephropathy. Am. J. Hypertens. 1997 10 : 202 8.
12. Anderson S, Rennke HG, Brenner BM. Nifedipine versus fosinopril in uninephrectomized diabetic rats. Kidney Int. 1992 41 : 891 7.
13. Li P, Kawachi H, Morioka T et al. Suppressive effects of sairei-to on monoclonal antibody 1-22-3-induced glomerulonephritis: Analysis of effective components. Pathol. Int. 1997 47 : 430 35.
14. Li P, Li PH, Zhang ZY. [Effect of chailing decoction and its active ingredients on experimental nephritis in rats]. Zhongguo Zhong Xi Yi Jie He Za Zhi 2003 23 : 757 9.
15. Liu XY. Therapeutic effect of chai-ling-tang (sairei-to) on the steroid-dependent nephrotic syndrome in children. Am. J. Chin. Med. 1995 23 : 255 60.
16. Kimura K, Nanba S, Tojo A, Matsuoka H, Sugimoto T. Effects of sairei-to on the relapse of steroid-dependent nephrotic syndrome. Am. J. Chin. Med. 1990 18 : 45 50.
17. Joarder ZH, Ogawa T, Yorioka N, Yamakido M. Studies on the effectiveness of sairei-to on puromycin aminonucleoside nephrosis in rats. Hiroshima J. Med. Sci. 1991 40 : 127 35.
18. Yoshikawa N, Ito H, Sakai T et al. [A prospective controlled study of sairei-to in childhood IgA nephropathy with focal/minimal mesangial proliferation. Japanese Pediatric IgA Nephropathy Treatment Study Group]. Nippon Jinzo Gakkai Shi 1997 39 : 503 6.
19. Kawachi H, Takashima N, Orikasa M, Oite T, Shimizu F. Effect of traditional Chinese medicine (sairei-to) on monoclonal antibody-induced proteinuria in rats. Pathol. Int. 1994 44 : 339 44.
20. Hattori T, Fujitsuka N, Kurogi A, Shindo S. [Sairei-to may inhibit the synthesis of endothelin-1 in nephritic glomeruli]. Nippon Jinzo Gakkai Shi 1997 39 : 121 8.
21. Suzuki J, Watanabe K, Kobayashi T et al. Effect of sairei-to on prostaglandin E2-induced phosphatidylinositol breakdown in aminonucleoside nephrotic rat. Nephron 1997 75 : 208 12.
22. Awazu M, Fujita H, Omori S, Hida M. The herbal medicine Sairei-to inhibits proliferation of rat mesangial cells. Nephron 2002 92 : 652 9.
23. Fujii O, Kanai T, Kouzuma S et al. Herbal medicines, Sairei-to and Tokishakuyaku-san, differently modulate the release of cytokines from decidual versus peripheral blood mononuclear cells. Am. J. Reprod. Immunol. 2001 46 : 369 72.
24. Ito T, Seo N, Yagi H et al. Unique therapeutic effects of the Japanese-Chinese herbal medicine, Sairei-to, on Th1/Th2 cytokines balance of the autoimmunity of MRL/lpr mice. J. Dermatol. Sci. 2002 28 : 198 210.
25. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 72 : 248 54.
26. Radford MG Donadio JV Bergstralh EJ, Grande JP. Predicting renal outcome in IgA nephropathy. J. Am. Soc. Nephrol. 1997 8 : 199 207.
27. Chomczynski P. A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Biotechniques 1993 15 : 532 4, 536 7.
28. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987 162 : 156 9.
29. Shen H, Huang G, Hadi M et al. Transforming growth factor-beta1 downregulation of Smad1 gene expression in rat hepatic stellate cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2003 285 : G539 46.
30. Roderick P. Epidemiology of end-stage renal disease. Clin. Med. 2002 2 : 200 4.
31. Taal MW, Brenner BM. Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists. Kidney Int. 2000 57 : 1803 17.
32. Ots M, Mackenzie HS, Troy JL, Rennke HG, Brenner BM. Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation. J. Am. Soc. Nephrol. 1998 9 : 224 30.
33. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 2001 345 : 861 9.
34. Peters H, Border WA, Noble NA. Targeting TGF-beta overexpression: Maximizing the antifibrotic actions of angiotensin II blockade in anti-Thy1 glomerulonephritis. Nephrol. Dial Transplant 1999 14 (Suppl 4 22 3.
35. Li P, Gong Y, Zu N, Li Y, Wang B, Shimizu F. Therapeutic mechanism of Saikosaponin-d in anti-Thy1 mAb 1-22-3 induced rat model of glomerulonephritis. Nephron 2005 101 : e111 18.
36. Yu L, Li JZ, Wang HY. [Progress in the study of the treatment of nephropathy with Astragalus and Angelica and their therapeutic mechanism]. Zhongguo Zhong Xi Yi Jie He Za Zhi 2001 21 : 396 9.
37. Li J, Yu L, Li N, Wang H. Astragalus mongholicus and Angelica sinensis compound alleviates nephrotic hyperlipidemia in rats. Chin. Med. J. (Engl.) 2000 113 : 310 14.
38. Sheng MX, Li JZ, Wang HY. [Therapeutic effect of Astragalus and Angelica on renal injury induced by ischemia/reperfusion in rats]. Zhongguo Zhong Xi Yi Jie He Za Zhi 2001 21 : 43 6.
39. Wang H, Li J, Yu L, Zhao Y, Ding W. Antifibrotic effect of the Chinese herbs, Astragalus mongholicus and Angelica sinensis, in a rat model of chronic puromycin aminonucleoside nephrosis. Life Sci. 2004 74 : 1645 58.
40. Massague J. The transforming growth factor-beta family. Annu. Rev. Cell Biol. 1990 6 : 597 641.
41. Mozes MM, Bottinger EP, Jacot TA, Kopp JB. Renal expression of fibrotic matrix proteins and of transforming growth factor-beta (TGF-beta) isoforms in TGF-beta transgenic mice. J. Am. Soc. Nephrol. 1999 10 : 271 80.
42. Yang CW, Yu CC, Ko YC, Huang CC. Aminoguanidine reduces glomerular inducible nitric oxide synthase (iNOS) and transforming growth factor-beta 1 (TGF-beta1) mRNA expression and diminishes glomerulosclerosis in NZB/W F1 mice. Clin. Exp. Immunol. 1998 113 : 258 64.
43. Shen H, Huang GJ, Gong YW. Effect of transforming growth factor beta and bone morphogenetic proteins on rat hepatic stellate cell proliferation and trans-differentiation. World J. Gastroenterol. 2003 9 : 784 7.